Surgery Partners, Inc. (SGRY): 14% SS Revenue Growth - Jefferies

August 10, 2016 9:28 AM EDT
Get Alerts SGRY Hot Sheet
Price: $18.00 --0%

Rating Summary:
    7 Buy, 3 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 30 | Down: 30 | New: 23
Trade SGRY Now!
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Jefferies analyst, Brian Tanqllut, reiterated his Buy rating on shares of Surgery Partners (NASDAQ: SGRY) after the company reported a strong Q2, headlined by a 14.4% increase in SS revenue. This bolsters his growth-driven bullish thesis on the stock.

As SGRY continues to execute on its strategy of driving growth through a combination of physician practice and ASC acquisitions and the expansion of service offerings, including emerging opportunities in orthopedics, the analyst expects the company to continue delivering very healthy top line and cash flow growth that would drive continued share upside.

No change to the price target of $27.00.

For an analyst ratings summary and ratings history on Surgery Partners click here. For more ratings news on Surgery Partners click here.

Shares of Surgery Partners closed at $16.43 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS Change, Analyst EPS View

Related Entities

Jefferies & Co

Add Your Comment